Should We Edit the Genetic Essence of Life?
By Margaret Somerville,
The Globe and Mail
| 06. 08. 2015
Untitled Document
The human germline is the genetic essence of human life. It’s the genes passed on from generation to generation that have evolved over billions of years since the advent of life on Earth which have resulted in each of us. We can now alter an embryo’s germline genes and all descendants of that embryo will inherit those alterations. Is that ethical?
The human germline’s been described as “the common heritage of humankind that must be held in trust for future generations.” Until very recently there was widespread agreement that intentional interference with it was unethical and should not be allowed. The UNESCO Universal Declaration on the Human Genome and Human Rights (1997) characterized germline interventions as “practices that could be contrary to human dignity;” the Council of Europe’s European Convention on Human Rights and Biomedicine (Oviedo Convention, 1997) bans interventions on the human genome that could be inherited, that is, on the human germline; the Canadian Assisted Human Reproduction Act 2004 prohibits “alter[ing] the genome of a cell of a human being or in-vitro embryo such that the...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...